Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

Description

Latrogenic infertility as a result of cancer treatment has a profound effect on long-term quality of life in survivors of reproductive-age cancers. Oocyte cryopreservation prior to cancer treatment has been associated with improved quality of life, with a potential ability to reduce long-term decision-related regret in cancer survivors. Though letrozole plus gonadotropin and and tamoxifen plus gonadotropin are currently routinely used worldwide in ovarian stimulation cycles for fertility preservation in patients with estrogen-receptor-positive breast cancer, it is not clear which of the two might lead to improved oocyte yield. Improved knowledge about the efficacy of these medications, with regard to oocyte yield, has the potential to significantly improve quality of life in reproductive-age breast cancer survivors.

Conditions

Infertility

Talk to us

Study Overview

On this page

Study Details

Study overview

Latrogenic infertility as a result of cancer treatment has a profound effect on long-term quality of life in survivors of reproductive-age cancers. Oocyte cryopreservation prior to cancer treatment has been associated with improved quality of life, with a potential ability to reduce long-term decision-related regret in cancer survivors. Though letrozole plus gonadotropin and and tamoxifen plus gonadotropin are currently routinely used worldwide in ovarian stimulation cycles for fertility preservation in patients with estrogen-receptor-positive breast cancer, it is not clear which of the two might lead to improved oocyte yield. Improved knowledge about the efficacy of these medications, with regard to oocyte yield, has the potential to significantly improve quality of life in reproductive-age breast cancer survivors.

Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

Condition
Infertility
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California at San Francisco, San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * New breast cancer diagnosis
  • * Has not yet begun chemotherapy
  • * Desires to undergo ovarian stimulation and oocyte retrieval prior to cancer treatment
  • * Age 18 years old or greater
  • * Chemotherapy has already commenced or been completed
  • * History of recurrent breast cancer (with a prior history of chemotherapy)
  • * Stage IV breast cancer diagnosis (metastases remote from the breast)
  • * Patient's oncologist advises against the trial - in which case they can choose to receive stimulation with letrozole+gonadotropin
  • * Does not plan to undergo ovarian stimulation and oocyte retrieval prior to diagnosis
  • * Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow-up, or interpretation of study results
  • * Age less than 18 years old

Ages Eligible for Study

18 Years to 50 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Mitchell Rosen, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2025-01-31